Phase 3 Readout~month

Phase 3 Topline: CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic

Indication
Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8

Other upcoming events for KYNB

Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or
Phase 3 ReadoutPhase 3 Topline: ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metasta
Phase 3 ReadoutPhase 3 Topline: Apa/Enza Short Study: Shortened 12 Months Duration of Androgen Receptor Signaling Agent in Combinati
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safet
Phase 3 ReadoutPhase 3 Topline: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F.

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic — KYNB Phase 3 Readout | BioSniper